Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT02810951 is registered in ClinicalTrials.gov with Castle Creek Biosciences, LLC. as lead sponsor.

NCT NCT02810951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02810951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Lead sponsor
Castle Creek Biosciences, LLC.
Phase
Phase 1/2
Overall status
Terminated
Start date
July 1, 2016
Completion date
April 18, 2022
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

epidermolysis bullosa dystrophica, recessive